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ABSTRACT
Universal access to sexual and reproductive 
health services is essential to facilitate the 
empowerment of women and achievement of 
gender equality. Increasing access to modern 
methods of contraception can reduce the 
incidence of unplanned pregnancy and decrease 
maternal mortality. Long- acting reversible 
contraceptives (LARCs) offer high contraceptive 
efficacy as well as cost- efficacy, providing 
benefits for both women and healthcare 
systems. The levonorgestrel- releasing intrauterine 
system (LNG- IUS) first became available in 
1990 with the introduction of Mirena (LNG- 
IUS 20), a highly effective contraceptive which 
can reduce menstrual blood loss and provide 
other therapeutic benefits. The impact of the 
LNG- IUS on society has been wide ranging, 
including decreasing the need for abortion, 
reducing the number of surgical sterilisation 
procedures performed, as well as reducing the 
number of hysterectomies carried out for issues 
such as heavy menstrual bleeding (HMB). In the 
context of the COVID-19 pandemic, Mirena can 
provide a treatment option for women with 
gynaecological issues such as HMB without 
organic pathology, minimising exposure to the 
hospital environment and reducing waiting times 
for surgical appointments. Looking to the future, 
research and development in the field of the 
LNG- IUS continues to expand our understanding 
of these contraceptives in clinical practice and 
offers the potential to further expand the choices 
available to women, allowing them to select the 
option that best meets their needs.
BACKGROUND
Sexual and reproductive health (SRH) 
constitutes a fundamental human right 
and plays a vital role in the empower-
ment of women and helping achieve 
gender equality. Universal access to SRH 
services is essential to achieving this objec-
tive.1 2 Increasing access to modern, effec-
tive methods of contraception can reduce 
the incidence of unplanned pregnancy, 
decrease maternal mortality, and can also 
contribute to fighting poverty.1 3 4
Long- acting reversible contraceptives 
(LARCs), such as implants, and hormonal 
and non- hormonal intrauterine devices 
(IUDs), are not only highly effective at 
preventing unintended pregnancy and 
subsequent abortion but are also cost- 
effective options that provide benefits for 
both women and healthcare systems.
Mirena (Bayer AG, Berlin, Germany) 
was the first levonorgestrel- releasing 
intrauterine system (LNG- IUS) of its kind. 
Developed by the Population Council’s 
International Committee for Contracep-
tion Research, Mirena (also termed LNG- 
IUS 20 based on the average in vivo LNG 
release rate over the first year5) became 
available in 1990 in Finland under the 
name Levonova. Mirena is a highly effec-
tive contraceptive, with a long- lasting but 
reversible effect that does not require a 
daily routine. It also reduces menstrual 
blood loss, which women often find bene-
ficial. Additionally, Mirena has thera-
peutic benefits; it is an effective treatment 
for heavy menstrual bleeding (HMB) 
without an organic cause and dysmenor-
rhoea, as well as providing endometrial 
protection for peri- and postmenopausal 
women receiving menopausal hormone 
therapy.
The impact of the LNG- IUS on society 
has been wide ranging: from decreasing 
the need for abortion (ie, unwanted 
pregnancy),6 7 to reducing the number 
of surgical sterilisation procedures 
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performed,8 as well as reducing the number of hyster-
ectomies carried out for issues such as HMB without 
an organic cause,9 10 allowing women to avoid an inva-
sive surgical procedure and maintain their fertility.
NOW MORE THAN EVER: THE ROLE OF LARCS IN 
THE CHANGING HEALTHCARE LANDSCAPE
With the COVID-19 pandemic causing widespread 
disruption to the provision of healthcare, including 
contraceptive services and supply chains, there are 
bound to be concerns regarding the potential for 
increased unintended pregnancies.11
Unlike short- acting methods such as oral contra-
ceptive pills, long- acting methods provide effective 
contraception for years after a single intervention that 
can mitigate concerns regarding access to and avail-
ability of contraceptive services.
As we seek to preserve capacity in healthcare systems 
and save valuable resources while increasing access 
to all, a shift towards medical treatment delivered in 
community settings for issues such as HMB is taking 
place in clinical practice. Medical options are less inva-
sive than surgical treatments, generally preserve fertility, 
and in most cases can be prescribed and implemented 
rapidly and easily. In the context of the COVID-19 
pandemic, the therapeutic benefits of Mirena provide 
an option for treating women with conditions such as 
HMB without an organic cause or dysmenorrhoea that 
minimises exposure to the hospital environment and 
reduces lengthy waits for surgical appointments.
BEYOND GYNAECOLOGICAL PRACTICE: HOW 
EFFECTIVE CONTRACEPTION CAN EMPOWER 
WOMEN
Increasing awareness and access to contraception 
can help women in low- income settings, by miti-
gating poverty and challenging gender inequalities. 
By providing discrete, effective contraception and 
reducing menstrual bleeding in the majority of users, 
the LNG- IUS can facilitate women’s increased produc-
tivity and participation in society, as well as reducing 
some of the issues caused by limited access to sanitary 
protection (menstrual poverty) and providing freedom 
from social stigma and exclusion.
Effective contraception for women living with 
comorbidities, such as HIV/AIDS or anaemia, is also 
vital to ensure a well- timed pregnancy that occurs 
when they are in optimal health and is not associated 
with further negative health consequences. Not only 
does Mirena contribute to preventing unplanned preg-
nancy in these women, but the associated decrease in 
menstrual blood loss can have the additional benefit of 
reducing exposure to infected blood in the context of 
HIV/AIDS,12 13 and improving the body’s iron stores in 
the context of anaemia.
The reduced number of visits to healthcare providers 
(eg, to obtain repeat prescriptions) and reduced need 
to purchase sanitary protection also decreases the 
economic burden both to women and the healthcare 
system.
By decreasing the amount of sanitary protection, 
packaging and other waste products, the LNG- IUS 
and other long- acting methods can also be seen as 
‘green contraceptives’ that reduce the traffic of non- 
biodegradable items to landfill sites.
THE FUTURE OF THE LNG-IUS AND PUBLIC 
HEALTH
With the popularity of LARCs, especially the LNG- 
IUS, continuing to increase it is good to know that 
research in this field is keeping pace. Real- world 
studies continue to deepen our understanding of 
how the LNG- IUS performs in clinical practice and 
further controlled trials offer the potential to expand 
or extend its use. Additionally, next- generation IUDs 
are being explored, which could further expand 
the options available to women, allowing them to 
choose the method that is best suited to their needs.14 
Moving forward, it seems reasonable to hope that 
with further developments and ongoing initiatives, 
access to LARCs will become a possibility for women 
across the globe.
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